GLP-1 and Sleep Apnea: Can Semaglutide Replace Your CPAP?

Obstructive sleep apnea — OSA — is one of the most undertreated conditions in medicine. An estimated 30 million Americans have it. Most aren't diagnosed. Of those who are and get a CPAP prescription, adherence is notoriously poor. The machine is uncomfortable, travel is a hassle, and many patients simply stop using it.

For the large majority of OSA patients whose apnea is driven by obesity, GLP-1 medications may be the most significant treatment advance in decades — not because they treat sleep apnea directly, but because they address the underlying cause.

The Connection Between Obesity and Sleep Apnea

Obstructive sleep apnea occurs when the airway collapses repeatedly during sleep, causing breathing cessation and arousal from sleep. It's measured by the Apnea-Hypopnea Index (AHI): the number of apnea/hypopnea events per hour.

• Mild OSA: AHI 5-14
• Moderate OSA: AHI 15-29
• Severe OSA: AHI 30+

The link between obesity and OSA is direct and mechanical. Excess fat tissue around the neck and throat increases the mass pressing on the airway. Visceral and pharyngeal fat reduces airway caliber and increases collapsibility during sleep. Inflammatory changes from obesity affect respiratory muscles. The result: every pound of excess weight increases OSA risk, and weight loss reliably reduces it.

The SURMOUNT-OSA Trial: A Landmark Result

In June 2024, the New England Journal of Medicine published the SURMOUNT-OSA trial, evaluating tirzepatide (Mounjaro/Zepbound) in adults with obesity and moderate-to-severe OSA.

The results were striking: - 55-62% reduction in AHI at 52 weeks (depending on CPAP use status) - Mean AHI dropped from ~51 events/hour to ~20 events/hour — from severe to moderate/mild territory - 42% of tirzepatide patients in the non-CPAP group reached AHI <5 (normal) at 52 weeks - Significant improvements in SBP, CRP (inflammation), and patient-reported sleep quality scores - Mean body weight reduction: approximately 20%

This is a level of OSA improvement that rivals or exceeds CPAP therapy for many patients — with the additional benefits of weight loss, metabolic improvement, and cardiovascular risk reduction.

The FDA took notice: in December 2024, tirzepatide (Zepbound) became the first medication approved by the FDA specifically for the treatment of moderate-to-severe OSA in adults with obesity. This is a significant regulatory milestone.

What About Semaglutide?

Semaglutide hasn't had as large a dedicated OSA trial as tirzepatide (SURMOUNT-OSA was specifically tirzepatide), but the weight loss mechanism is the same. Real-world and clinical trial data on semaglutide consistently show significant improvements in OSA severity in proportion to weight loss achieved.

The STEP trials, which studied semaglutide for weight loss, included assessments of obesity-related comorbidities including sleep quality. Patients who lost substantial weight on semaglutide consistently reported improved sleep, and objective measures of OSA improved in proportion to weight reduction.

Mechanistically, semaglutide and tirzepatide work through the same pathway (GLP-1 receptor agonism), and tirzepatide adds GIP receptor agonism for greater weight loss. The OSA improvements are largely weight-mediated, so the degree of improvement correlates with the degree of weight loss.

Who Stands to Benefit Most

The patients most likely to see dramatic OSA improvement with GLP-1 therapy are:

• Those with weight-related (positional or obesity-driven) OSA rather than anatomical/skeletal airway abnormalities
• Men — who have higher rates of OSA and are more likely to have obesity-related OSA
• Those with BMI ≥30 (or ≥27 with comorbidities) who have significant weight to lose
• Patients who are CPAP non-adherent and need an alternative path

Patients whose OSA is driven primarily by anatomical factors (jaw position, nasal anatomy, tonsillar hypertrophy) may see less dramatic improvement from weight loss alone, though they still benefit from the metabolic effects of GLP-1 therapy.

The CPAP Question

The one thing to be clear about: don't stop CPAP based on feeling better or assumed improvement. Subjective sleep quality improvement can outpace objective AHI normalization. The airway risks of untreated OSA — cardiovascular stress, hypoxia, cardiac arrhythmias — are real.

The right path: 1. Start GLP-1 therapy for weight loss and OSA as comorbidity 2. Continue CPAP as prescribed during the weight loss period 3. After significant weight loss (typically 6-12 months of therapy), request a follow-up sleep study 4. If AHI has normalized or reduced to mild range, discuss CPAP cessation with your sleep physician

The goal is objective, documented improvement — not just feeling better, which many people do even with ongoing OSA.

Beyond OSA: Sleep Quality on GLP-1

Even in patients without formal OSA, sleep quality consistently improves on GLP-1 therapy. Patients report falling asleep faster, fewer nighttime awakenings, more energy upon waking. Some of this is OSA improvement. Some is the metabolic normalization — reduced inflammation, improved glycemic control, and reduced cortisol dysregulation all contribute to better sleep architecture.

If your sleep quality is poor and you have excess weight, treating the metabolic root cause with GLP-1 therapy addresses multiple contributing factors simultaneously.

The Takeaway

GLP-1 medications are proving to be one of the most effective treatments for obesity-related OSA in the history of the condition. The 55-62% reduction in AHI from SURMOUNT-OSA is remarkable — an effect size that has real clinical consequences for cardiovascular risk, cognitive function, energy, and quality of life.

If you have OSA and carry excess weight, GLP-1 therapy addresses the root cause. If you've been CPAP-avoidant, this may be the path to actually treating your sleep apnea in a sustainable way.